While CAR T cell therapies have shown success primarily in hematologic malignancies, new advances are emerging for gastrointestinal (GI) solid tumors such as colorectal, gastric, and esophageal cancers. U.S. research teams have reported promising preclinical and early clinical data targeting solid tumor antigens like CLDN18.2, demonstrating preliminary safety and efficacy.
Overcoming challenges such as the tumor microenvironment and antigen selection has long been a barrier for CAR T cells in solid tumors. These findings may represent an important step forward toward broader clinical application. Further clinical trials are anticipated.
Source: Drug Discovery News (June 2025), Article Link
【My Thoughts】
Expanding CAR T cell therapy into solid tumors has long been a major challenge. The recent focus on novel antigens such as CLDN18.2 is gradually making clinical application more feasible. Progress in GI tumors may serve as a turning point for broader solid tumor immunotherapy. Managing safety and achieving durable responses will be critical in future development.
